Morteza Sarmadi

Morteza Sarmadi

Auto-generated profile, based on publicly available information

Morteza Sarmadi

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
XLXueguang Lu
Xueguang Lu
LMLei Miao
Lei Miao
WGWenting Gao
Wenting Gao
ZCZiqi Chen
Ziqi Chen
KMKevin J. McHugh
Kevin J. McHugh
AJAna Jaklenec
Ana Jaklenec
Microfabricated particles mimic multiple intratumoral injections of STING agonist over weeks to improve ease of use and decrease metastasis.

10 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MSMorteza Sarmadi
Morteza Sarmadi
ABAdam M. Behrens
Adam M. Behrens
KMKevin J. McHugh
Kevin J. McHugh
HCHannah T. M. Contreras
Hannah T. M. Contreras
ZTZachary L. Tochka
Zachary L. Tochka
AJAna Jaklenec
Ana Jaklenec
We investigate particle injectability as an essential parameter for design of microparticle-based drug delivery systems.

15 July 2022 in Science Advances
Verified
Journal Article
Open access
MSMorteza Sarmadi
Morteza Sarmadi
CTChristina Ta
Christina Ta
AVAbigail M. VanLonkhuyzen
Abigail M. VanLonkhuyzen
DFDominique C. De Fiesta
Dominique C. De Fiesta
MKMaria Kanelli
Maria Kanelli
AJAna Jaklenec
Ana Jaklenec
Next-generation therapeutics require advanced drug delivery platforms with precise control over morphology and release kinetics. A recently developed microfabrication technique enables fabrication of a new class of injectable microparticles with a hollow core-shell structure that displays pulsatile release kinetics, providing such capabilities. Here, we study this technology and the resulting core-shell microstructures. We demonstrated that pulsatile release is governed by a sudden increase in porosity of the polymeric matrix, leading to the formation of a porous path connecting the core to the environment. Moreover, the release kinetics within the range studied remained primarily independent of the particle geometry but highly dependent on its composition. A qualitative technique was developed to study the pattern of pH evolution in the particles. A computational model successfully modeled deformations, indicating sudden expansion of the particle before onset of release. Results of this study contribute to the understanding and design of advanced drug delivery systems.

8 March 2024 in Science Advances
Verified
Journal Article
Open access
SAShahad K. Alsaiari
Shahad K. Alsaiari
SNSeba Nadeef
Seba Nadeef
JDJohn L. Daristotle
John L. Daristotle
WRWilliam Rothwell
William Rothwell
BDBujie Du
Bujie Du
AJAna Jaklenec
Ana Jaklenec
Nanomaterials offer unique opportunities to engineer immunomodulatory activity. In this work, we report the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework–8 (ZIF-8). The accumulation of ZIF-8 in endosomes and the pH-responsive release of its subunits enable selective engagement with endosomal Toll-like receptors, minimizing the risk of off-target activation. The intrinsic adjuvant properties of ZIF-8, along with the efficient delivery and biomimetic presentation of a severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain trimer, primed rapid humoral and cell-mediated immunity in a dose-sparing manner. Our study offers insights for next-generation adjuvants that can potentially impact future vaccine development.

29 February 2024 in Journal of Student Research
Verified
Journal Article
Open access
WAWilliam Anderson
William Anderson
MSMorteza Sarmadi
Morteza Sarmadi
Recent developments in microfluidics and biomaterials have enabled the creation of organs-on-chips (OoCs), which provide a controlled and lifelike in vitro microenvironment resembling an actual organ. Organ-on-a-chip technology offers a tremendous opportunity for efficient, cost-effective, and ethical drug testing and research. However, the high throughput and large quantities of data these complex microenvironments produce make it difficult for researchers to effectively analyze the data and draw valuable conclusions. Convolutional Neural Networks (CNNs) are most aptly positioned to address many of OoC’s challenges because of their ability to interpret microscopic images and facilitate the analytical process. Despite the growing field of AI, there have been a limited number of studies summarizing the various applications of CNNs in OoCs. This review aims to provide 1) an overview of the technology involved with CNNs and OoCs 2) an insight into the state-of-the-art applications of CNNs in OoCs including device parameters, predicting and tracking cell trajectories, super-resolution image segmentation, and image classification, and 3) an overview of existing challenges and opportunities ahead for clinical translation of this technology. Various applications of CNNs have been classified by the type of task. Different CNN models such as Faster R-CNNs, fully convolutional networks (FCNs), and Mask R-CNNs are explained and highlighted. This review article can be used as a resource for a better understanding of the potential of CNNs in biomedical research and clinical applications, particularly OoCs.